Alaunos Therapeutics, Inc. announced that the Company will present at the 2nd Hawaii Global Summit on Thoracic Malignancies taking place June 27 - July 1, 2023. Alaunos Director of Translational Sciences Matthew Collinson-Pautz, Ph.D., will discuss the Company's TCR-T therapy in solid tumors targeting specific, cancer-driving mutations currently being evaluated in a Phase 1/2 open-label, dose-escalation trial at The University of Texas MD Anderson Cancer Center. Details of the presentation are as follows: Title: Neoantigen Targeting TCR Engineered Cellular Therapy for RAS-mutant Tumors.

Session Title: Cellular Therapy. Presentation Date and Time: June 30, 11:27 a.m. HST. Presenter: Dr. Collinson-Pautz.

This summit brings together esteemed translational and clinical researchers, as well as community oncologists, to address the challenges and advancements in the dynamic field of lung cancer and the evolution of therapeutic approaches. The TCR-T Library Phase 1/2 trial is an open-label, dose-escalation trial being conducted at MD Anderson. The trial is actively enrolling patients with NSCLC, colorectal, endometrial, pancreatic, ovarian and bile duct cancers that have a matching human leukocyte antigen (HLA) whose tumors contain at least one of the targeted driver mutations in KRAS, TP53 and EGFR.